ArticleRand health quarterly2019
Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment.
Article in Rand health quarterly, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence.The journal of prevention of Alzheimer's disease · 2026Pooled it
- Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?Neurology · 2023Trial
- Design and synthesis of carbazole-acrylamide-pyridinium hybrids as dual acetylcholinesterase/butyrylcholinesterase inhibitors and evaluation of their cytotoxic profile on SH-SY5Y and HEK293 cell lines.RSC medicinal chemistry · 2026Article
- Adapting the spanish healthcare system for disease-modifying treatments in early-stage alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Review
- Beyond the Cochrane review: Re-evaluating anti-amyloid therapy in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Observational
- Brain health care accelerator: A primary care-centered model for scaling dementia diagnosis and care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Eligibility for lecanemab treatment in a French memory clinic setting.Journal of neurology · 2026Observational
- Predicting rates of cognitive and functional decline in Alzheimer's disease and mild cognitive impairment.Communications medicine · 2026Article
- Evaluating dementia risk prediction in mild cognitive impairment: an early health technology assessment of the AI-Mind tool.GeroScience · 2026Article
- FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?International journal of molecular sciences · 2026Review
- Acceptable standards for clinic-based digital cognitive assessments: Recommendations from the Global CEO Initiative on Alzheimer's Disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer's Disease: A U.S. Cost Comparison Model.Neurology and therapy · 2025Article
- Speech-language therapy and occupational therapy for patients with mild cognitive impairment and dementia: a retrospective cohort study using German health claims data.BMC health services research · 2025Article
- Scaling Alzheimer's Care: The Case for Specialized Treatment Clinics.Journal of the American Geriatrics Society · 2025Article
- Associations of Plasma p-tau181 With Age, Adjusted for Kidney Function and Sociodemographic Factors.International journal of geriatric psychiatry · 2025Article
- The patient pathway for mild cognitive impairment due to Alzheimer's disease in Asia: Current practices, barriers, and expert recommendations for optimization.The journal of prevention of Alzheimer's disease · 2025Article
- A Stakeholder-Engaged Process to Design and Implement the Assessment of Cognitive Complaints Toolkit for Alzheimer's Disease (ACCT-AD) in Primary Care.Research square · 2025Article
- Early Dysregulation of RNA Splicing and Translation Processes Are Key Markers from Mild Cognitive Impairment to Alzheimer's Disease: An In Silico Transcriptomic Analysis.International journal of molecular sciences · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No disease-modifying therapy is currently available for Alzheimer's disease, but therapies are in development, and one may become available in the near future. Based on results from early-stage clinical trials, therapeutic development has focused on the hypothesis that Alzheimer's dementia must be prevented rather than cured, because candidate treatments have not been able to reverse the course of dementia. Thus, current trials target patients with early-stage Alzheimer's disease. Were a therapy to become available, patients could undergo first screening for signs of early-stage memory loss or mild cognitive impairment (MCI), testing for the Alzheimer's disease pathology, and then treatment with the aim of halting or slowing progression to Alzheimer's dementia. An important health systems challenge will arise if this new treatment paradigm bears out in late-stage clinical trials. In the 28 European Union countries, we estimate that approximately 20 million individuals over age 55 have MCI, although most people have not been tested for disease pathology. Thus, when a therapy first becomes available, there would be a substantial number of existing (or prevalent) MCI patients who would require screening, diagnosis, and then treatment as quickly as possible to prevent the progression to full-blown Alzheimer's dementia. This research analyzes the preparedness of the health care systems in six European countries-France, Germany, Italy, Spain, Sweden, and the United Kingdom-to ensure timely diagnosis and treatment of patients if a disease-modifying therapy for Alzheimer's becomes available.
Indexed as
Identifiers
31205802PMC6557037What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.